Arvinas, Inc. (NASDAQ:ARVN) CAO Sells $20,334.50 in Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David K. Loomis sold 1,214 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.75, for a total value of $20,334.50. Following the completion of the transaction, the chief accounting officer now directly owns 18,863 shares in the company, valued at approximately $315,955.25. This represents a 6.05 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Arvinas Price Performance

ARVN stock opened at $16.75 on Tuesday. The company has a market capitalization of $1.15 billion, a PE ratio of -6.05 and a beta of 1.88. Arvinas, Inc. has a 12 month low of $16.07 and a 12 month high of $51.51. The firm’s 50-day moving average is $18.44 and its 200 day moving average is $22.85.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter last year, the firm earned ($2.53) EPS. Sell-side analysts forecast that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on ARVN. BMO Capital Markets reiterated an “outperform” rating and issued a $82.00 price objective (down previously from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. Wedbush reaffirmed an “outperform” rating and set a $57.00 target price on shares of Arvinas in a report on Tuesday, February 11th. Guggenheim reiterated a “buy” rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research report on Wednesday, December 11th. Finally, BTIG Research started coverage on Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. Twelve investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $60.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. purchased a new stake in shares of Arvinas in the 4th quarter worth approximately $28,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares in the last quarter. KBC Group NV lifted its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the period. Quantbot Technologies LP boosted its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after acquiring an additional 2,601 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Arvinas in the 4th quarter valued at $171,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.